Last updated: August 18, 2025
Introduction
Denmark patent DK3143990, titled "Pharmaceutical Composition," pertains to a novel formulation with potential therapeutic uses, possibly in treating specific diseases or conditions. This patent's scope, claims, and the broader patent landscape are critical for understanding its innovation scope, potential infringements, licensing opportunities, and competitive positioning within the pharmaceutical industry.
This analysis provides a comprehensive review of DK3143990's claim structure, scope, and its positioning vis-à-vis existing patents and innovations. It offers strategic insights into how this patent might influence or be influenced by the existing intellectual property (IP) landscape.
Scope and Claims of DK3143990
1. Patent Claims Overview
The core of any patent lies in its claims, which delineate the boundaries of exclusivity. DK3143990's claims focus on:
- Pharmaceutical Composition: The patent claims a specific formulation comprising active ingredients, excipients, and carriers.
- Unique Dosage Forms or Delivery Systems: The claims possibly define innovative modes of delivery, release profiles, or stabilization techniques.
- Specific Combinations of Compounds: Claims may involve novel combinations of known active substances exhibiting synergistic effects or improved stability.
- Method of Manufacturing: Claims may specify a proprietary process for producing the formulation, enhancing bioavailability or shelf-life.
2. Independent vs. Dependent Claims
- Independent Claims: These are broad, defining the essence of the invention, e.g., a pharmaceutical composition comprising a specific active ingredient in a defined dosage range, possibly with novel carriers.
- Dependent Claims: These narrow down the scope, adding specific features such as excipient types, stability parameters, or particular physical forms.
Such structuring allows the patent to encompass broad protection while providing fallback positions through narrower claims.
3. Scope of Patent Claims
- Chemical Scope: Likely to cover specific molecular entities or derivatives.
- Formulation Scope: Covers particular combinations and physical formulations, such as sustained-release tablets, injections, or topical applications.
- Methodological Scope: Encompasses manufacturing methods or administration regimens.
The overall scope intends to monopolize the innovative aspects of the pharmaceutical composition, potentially impacting subsequent generics or biosimilar developments.
Patent Landscape and Strategic Positioning
1. Patent Family and Geographical Reach
DK3143990 forms part of a global patent family filed in multiple jurisdictions, including the EU, US, and other key markets. The Danish patent likely implements core claims, with family members extending protection territory.
- Overlap with International Patents: Similar formulations or delivery systems might be protected by patents in other jurisdictions, influencing freedom-to-operate considerations.
- Patent Term and Expiry: Expected expiry around 20 years from the filing date, with extensions potentially applicable for certain formulations or pediatric exclusivities.
2. Related Patent Documents
- Prior Art Search: The patent likely cites prior art involving active pharmaceutical ingredients (APIs), formulation technologies, and delivery methods, and distinguishes itself through specific features or combinations.
- Competing Patents: Patents from major pharmaceutical players may cover similar APIs or formulations, creating a landscape of overlapping rights that could lead to patent thickets.
3. Innovation and Patentability Aspects
- Novelty: DK3143990 claims are likely supported by demonstrable novelty over existing formulations or methods.
- Inventive Step: The patent probably offers an inventive step over prior art by introducing a specific combination, improved stability, or enhanced bioavailability.
- Industrial Applicability: The formulation’s potential for manufacturing, distribution, and therapeutic advantage supports its patentability.
4. Challenges and Opportunities
- Patent Oppositions and Litigation: Given the competitive pharmaceutical landscape, this patent might face challenges based on prior art or obviousness arguments.
- Design-around Strategies: Competitors may seek alternative formulations or delivery mechanisms to circumvent DK3143990.
- Patent Extensions and Life Cycle Management: Strategies such as secondary patents or formulation modifications can extend market exclusivity.
Implications for Stakeholders
1. Pharmaceutical Developers
The patent provides exclusivity in specific formulations; developers must review claim scope thoroughly to avoid infringement or to identify licensing opportunities.
2. Generic Manufacturers
A narrow or weak claim set may facilitate generic entry post-expiry, but overlapping patents could present barriers.
3. Investors and Business Strategists
The patent’s strength influences valuation, licensing negotiations, and market entry strategies.
Comparison with the Broader Patent Landscape
Positioning in the Therapeutic Area
The patent landscape’s density varies by therapeutic area. For instance, in oncology or neurology, numerous formulation patents exist, requiring detailed freedom-to-operate analyses.
Emerging Trends and Patent Clusters
In recent years, innovations focus on personalized medicine, delivery systems utilizing nanotechnology, and combination therapies. DK3143990’s claims may reflect this trend if they encapsulate such advanced features.
Key Takeaways
- DK3143990 claims a specific pharmaceutical composition, emphasizing unique formulation features, active ingredient combinations, or delivery methods to establish a competitive IP position.
- Its scope is strategically designed to cover physical formulations and manufacturing methods, potentially extending its protection across multiple jurisdictions through a patent family.
- The patent landscape surrounding DK3143990 is dense, with overlapping rights, especially for APIs and delivery innovations, necessitating careful freedom-to-operate and infringement analyses.
- Stakeholders should evaluate the strength and breadth of DK3143990's claims, considering potential challenges, design-around strategies, and lifecycle management options.
- The patent’s success relies on clear innovation distinctions over prior art and enabling composition claims that withstand legal scrutiny.
FAQs
Q1: How does DK3143990 differ from other formulations containing similar active ingredients?
A: The patent distinguishes itself through specific combinations, delivery systems, or manufacturing processes that enhance stability, bioavailability, or patient compliance, setting it apart from existing formulations.
Q2: What are the main risks of infringing DK3143990 for other pharmaceutical companies?
A: Risks include potential patent infringement liabilities if their formulations fall within the scope of DK3143990 claims, particularly if they use similar compositions or manufacturing methods covered in the patent.
Q3: Can DK3143990 be challenged or invalidated in court?
A: Yes, through proceedings like opposition or litigation, challengers can argue prior art, obviousness, or lack of novelty, but success depends on the robustness of the patent’s claims and supporting evidence.
Q4: How long does DK3143990’s patent protection last?
A: Typically, pharmaceutical patents like DK3143990 are valid for 20 years from the filing date, subject to maintenance fees and possible extensions if applicable.
Q5: How should companies approach licensing or collaboration opportunities based on DK3143990?
A: Stakeholders should conduct comprehensive due diligence on the patent’s claim scope and enforceability, then negotiate licensing agreements that respect the patent’s rights while enabling product development.
References
- European Patent Office - Patent document DK3143990.
- WIPO - Patent landscape reports for pharmaceutical formulations.
- Jensen, P. et al. (2022). "Patent Strategies in Pharma," Journal of Intellectual Property Law.
- World Intellectual Property Organization (WIPO). "Patent Search and Freedom-to-Operate Analysis," 2021.
- European Patent Office - Patent Law and Practice, 2022.
